Low-dose immunotherapy as a potentiator to increase the response with neo-adjuvant chemotherapy in oral cancers.
World J Clin Cases
; 11(17): 3976-3979, 2023 Jun 16.
Article
em En
| MEDLINE
| ID: mdl-37388807
ABSTRACT
Neo-adjuvant chemotherapy (NACT) is utilized in locally advanced oral cancers to reduce the tumor burden and downstage the tumor to be amenable for definitive surgical management. Its long-term results compared to upfront surgical resection was not encouraging. Immunotherapy has now been used not only in recurrence and metastatic setting but also in the locally advanced tumor management regimens. The purpose of this concept paper is to bring forward the rationale to use a fixed low-dose immunotherapy agent as a potentiator to the standard NACT regimen and recommend their future investigation in oral cancer management.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
World J Clin Cases
Ano de publicação:
2023
Tipo de documento:
Article